DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2022-07-05

Last Posted Date: 2024-07-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT05443191

Locations: 🇫🇮
Aava Lääkärikeskus - Aava Kamppi, Annankatu 32, 00100 Helsinki, Finland, Helsinki,, Finland
🇫🇮
Master Centre for Finland, Helsinki, Finland, Finland
🇫🇷
Master centre for France_Paris La défense cedex, Paris, La Défense, France

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Phase 2

Active, not recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions: Drug: NNC6019-0001
Drug: Placebo (NNC6019-0001)

First Posted Date: 2022-07-01

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 99

Registration Number: NCT05442047

Locations: 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇪🇸
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
🇩🇪
Uniklinik Münster, Klinik für Kardiologie I, Münster, Germany

and more 29 locations

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

Withdrawn

Conditions: Obesity

Interventions: Drug: Liraglutide

First Posted Date: 2022-06-29

Last Posted Date: 2023-01-25

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT05438186

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: IcoSema
Drug: insulin icodec
Drug: semaglutide

First Posted Date: 2022-06-28

Last Posted Date: 2025-03-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT05435677

Locations: 🇨🇳
Peking University Third Hospital, Northern branch-Phase I, Beijing, Beijing, China

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Semaglutide
Drug: Semaglutide/dapagliflozin
Drug: Dapagliflozin

First Posted Date: 2022-06-23

Last Posted Date: 2024-08-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 152

Registration Number: NCT05429593

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Brandenburg, Germany
🇩🇪
Parexel International GmbH, Berlin, Germany

Awareness, Care & Treatment In Obesity Management - An Observation in Mainland China

Completed

Conditions: Obesity

Interventions: Other: no treatment given

First Posted Date: 2022-06-23

Last Posted Date: 2023-03-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 8000

Registration Number: NCT05428501

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, China

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: NDec - oral decitabine-tetrahydrouridine
Drug: HU - Hydroxyurea
Drug: Placebo

First Posted Date: 2022-06-06

Last Posted Date: 2025-05-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT05405114

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
East Carolina University_Greenville_0, Greenville, North Carolina, United States
🇺🇸
Univ Oklahoma HSC_Okla City, Oklahoma City, Oklahoma, United States

and more 80 locations

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Phase 3

Completed

Conditions: Overweight
Obesity
Type 2 Diabetes Mellitus

Interventions: Drug: Cagrilintide
Drug: Placebo cagrilintide
Drug: Placebo semaglutide
Drug: Semaglutide

First Posted Date: 2022-05-27

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1200

Registration Number: NCT05394519

Locations: 🇺🇸
Albany Medical College - Endo, Albany, New York, United States
🇺🇸
Texas Diab & Endo, P.A., Austin, Texas, United States
🇺🇸
Velocity Clinical Res-Dallas, Dallas, Texas, United States

and more 154 locations

A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

Phase 1

Completed

Conditions: Chronic Kidney Disease and Systemic Inflammation

Interventions: Drug: Placebo
Drug: Ziltivekimab

First Posted Date: 2022-05-18

Last Posted Date: 2025-03-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT05379829

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Zhongda Hospital Southeast University-Nephrology, Nanjing, Jiangsu, China

and more 3 locations

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: NNC0487-0111 A
Drug: NNC0487-0111 B
Other: Placebo A (NNC0487-0111 A)
Other: Placebo B (NNC0487-0111 B)

First Posted Date: 2022-05-11

Last Posted Date: 2024-07-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 144

Registration Number: NCT05369390

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy